Malignancy and mortality in paediatric‐onset inflammatory bowel disease: a 3‐year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN
暂无分享,去创建一个
G. Veres | P. Lionetti | K. Kolho | D. Turner | S. Koletzko | R. Shaoul | M. Aardoom | A. Levine | M. Aloi | J. Bronský | L. de Ridder | F. Ruemmele | C. Braegger | J. Martín-de-Carpi | U. Fagerberg | D. Serban | G. Veereman | D. Wilson | A. Hauer | I. Hojsak | E. Trindade | M. Joosse | S. Hussey | C. Tzivinikos | H. Garnier-Lengliné | P. Kemos | A. D. de Vries | C. Spray | R. S. Boneh | M. Joosse | M. Sładek | E. Roma-Giannikou | I. Davies | A. V. Wewer | R. Sigall Boneh | C. Sarbagili Shabat | L. Ridder | C. Shabat | E. Roma‐Giannikou | Arie Levine | C. Braegger | David C. Wilson | C. Spray | Ron Shaoul | Dan Turner | Daniela Elena Serban | Gábor Veres | Eunice Trindade | A. C. D. Vries
[1] E. G. Nabel,et al. National Cancer Institute , 2020, Definitions.
[2] M. Neovius,et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014 , 2017, British Medical Journal.
[3] S. Hutfless. Increased risk of cancer in children with inflammatory bowel disease , 2017, British Medical Journal.
[4] A. Griffiths,et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.
[5] Eva Steliarova-Foucher,et al. International incidence of childhood cancer, 2001–10: a population-based registry study , 2017, The Lancet. Oncology.
[6] D. Tanyingoh,et al. Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases , 2017, The American Journal of Gastroenterology.
[7] K. Young,et al. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. , 2017, Annals of diagnostic pathology.
[8] P. Seksik,et al. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.
[9] M. Neovius,et al. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study , 2017, BMC Gastroenterology.
[10] J. Gisbert,et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] G. Veres,et al. Malignancy and Mortality in Pediatric Patients with Inflammatory Bowel Disease: A Multinational Study from the Porto Pediatric IBD Group , 2014, Inflammatory bowel diseases.
[12] J. Ariyaratnam,et al. Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis , 2014, The American Journal of Gastroenterology.
[13] A. Amiot,et al. European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[14] G. Veres,et al. ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.
[15] L. Dauchet,et al. Mortality and Cancer in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Study , 2013, The American Journal of Gastroenterology.
[16] J. González,et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.
[17] G. Raca,et al. &ggr;&dgr; Hepatosplenic T-Cell Lymphoma in a Pediatric Patient With Crohn’s Disease on Combined Immunosuppressive and Immunomodulator Therapy , 2012 .
[18] David C Wilson,et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.
[19] M. V. van Oijen,et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease , 2011, Gut.
[20] L. Peyrin-Biroulet,et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease , 2011, Gut.
[21] A. McMahon,et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. , 2010, Arthritis and rheumatism.
[22] D. Patterson,et al. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. , 2010, Clinical lymphoma, myeloma & leukemia.
[23] F. Carrat,et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.
[24] H. Drummond,et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. , 2008, Gastroenterology.
[25] P. Lakatos,et al. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? , 2006, Postgraduate Medical Journal.
[26] M. Brydolf,et al. Incidence and prevalence of inflammatory bowel disease in children in South‐Western Sweden , 1994, Acta paediatrica.
[27] H. Adami,et al. Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.
[28] M. Frisch,et al. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[30] B. Weiss,et al. Disease Behavior in Children with Crohn’s Disease: The Effect of Disease Duration, Ethnicity, Genotype, and Phenotype , 2008, Digestive Diseases and Sciences.